Arena Pharmaceuticals, Inc. (ARNA), Biogen Idec Inc. (BIIB): More Than an Obesity Drug Company

Page 2 of 2

But in the short term, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is still highly dependent on Belviq. The biotech has a market cap of $1.8 billion; a company with three phase 1 compounds is only worth a tenth of that. It remains to be seen whether Arena and Eisai can compete with VIVUS, Inc. (NASDAQ:VVUS)‘ Qsymia, which produces greater weight loss but with potential for more severe side effects.

At least Arena has a backup plan.

The article More Than an Obesity Drug Company originally appeared on Fool.com is written by Brian Orelli .

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2